Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).

被引：0
作者：
Berghoff, A.
Bartsch, R.
Bago-Horvath, Z.
Dubsky, P. C.
Rudas, M.
Pluschnig, U.
Wiltschke, C.
Gnant, M.
Steger, G. G.
Zielinski, C.
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria
[7] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
[41]   HER3 STATUS BY IMMUNOHISTOCHEMISTRY (IHC) IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) TREATED WITH TRASTUZUMAB (T) ± CHEMOTHERAPY (CT): CORRELATION WITH CLINICAL OUTCOME [J].
Gori, Stefania ;
Sidoni, Angelo ;
Colozza, Mariantonietta ;
Mameli, Maria Grazia ;
Fenocchio, Daniela ;
Minenza, Elisa ;
Foglietta, Jennifer ;
Stocchi, Lucia ;
De Angelis, Verena ;
Crino, Lucio .
ANNALS OF ONCOLOGY, 2009, 20
[42]   Targeted Therapy in HER2-Positive Breast Cancer [J].
Thill, Marc ;
Kraft, Clayton ;
Friedrich, Michael .
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) :295-302
[43]   Therapy for HER2-Positive Metastatic Breast Cancer [J].
Dekker, Tim J. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25)
[44]   The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast [J].
Lewis, G. D. ;
Haque, W. ;
Farach, A. ;
Hatch, S. S. ;
Butler, E. B. ;
Schwartz, M. R. ;
Bonefas, E. ;
Teh, B. S. .
CANCER RESEARCH, 2019, 79 (04)
[45]   The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast [J].
Lewis, Gary D. ;
Haque, Waqar ;
Farach, Andrew ;
Hatch, Sandra S. ;
Butler, E. Brian ;
Niravath, Polly A. ;
Schwartz, Mary R. ;
Bonefas, Elizabeth ;
Teh, Bin S. .
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2021, 26 (02) :179-187
[46]   Docetaxel, Carboplatin and Trastuzumab (TCH) as Neoadjuvant (neoadj) Therapy in Patients (pts) with HER2-positive (HER2+) Operable Breast Cancer (BrCa) [J].
Zuradelli, M. ;
Gullo, G. ;
Walshe, J. ;
Defrein, A. M. ;
Healy, J. ;
Kalachand, R. ;
Murray, H. ;
Sclafani, F. ;
Crown, J. P. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 :S177-S177
[47]   Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer [J].
Griguolo, Gaia ;
Pascual, Tomas ;
Dieci, Maria Vittoria ;
Guarneri, Valentina ;
Prat, Aleix .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[48]   Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer [J].
Matusz-Fisher, Ashley ;
Tan, Antoinette R. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (03) :385-395
[49]   HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future [J].
Xu, Luying ;
Xie, Yuxin ;
Gou, Qiheng ;
Cai, Rui ;
Bao, Rong ;
Huang, Yucheng ;
Tang, Ruisi .
FRONTIERS IN PHARMACOLOGY, 2024, 15
[50]   Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer [J].
Zongbi Yi ;
Guohua Rong ;
Yanfang Guan ;
Jin Li ;
Lianpeng Chang ;
Hui Li ;
Binliang Liu ;
Wenna Wang ;
Xiuwen Guan ;
Quchang Ouyang ;
Lixi Li ;
Jingtong Zhai ;
Chunxiao Li ;
Lifeng Li ;
Xuefeng Xia ;
Ling Yang ;
Haili Qian ;
Xin Yi ;
Binghe Xu ;
Fei Ma .
npj Breast Cancer, 6
12345